Sign in

mmonrealriete

@mmonrealriete.bsky.social
27 followers 30 following 57 posts

PI of the #RIETEregistry

PostsRepliesMedia
mmonrealriete @mmonrealriete.bsky.social · 09/12/2025
010
mmonrealriete @mmonrealriete.bsky.social · 09/12/2025
010
mmonrealriete @mmonrealriete.bsky.social · 09/12/2025
010
mmonrealriete @mmonrealriete.bsky.social · 07/12/2025
Should we manage VTE the same way in women with breast, ovarian, or uterine cancer? Data from the #RIETEregistry — coming soon in RPTH
000
mmonrealriete @mmonrealriete.bsky.social · 20/11/2025
020
mmonrealriete @mmonrealriete.bsky.social · 20/11/2025
010
mmonrealriete @mmonrealriete.bsky.social · 14/11/2025
010
mmonrealriete @mmonrealriete.bsky.social · 14/11/2025
Congrats, Romain and team!
000
mmonrealriete @mmonrealriete.bsky.social · 07/11/2025
010
mmonrealriete @mmonrealriete.bsky.social · 07/11/2025
Appearing soon in RPTH
020
mmonrealriete @mmonrealriete.bsky.social · 22/10/2025
Enoxaparin vs Tinzaparin or Dalteparin in cancer patients with VTE The #RIETEregistry experience appearing soon in RPTH
010
mmonrealriete @mmonrealriete.bsky.social · 15/10/2025
000
mmonrealriete @mmonrealriete.bsky.social · 15/10/2025
000
Reposted by mmonrealriete
Behnood Bikdeli, MD, MS @bbikdeli.bsky.social · 29/09/2025
Fibrinolytic Therapy for Thromboembolic Diseases: Approved Indications and Future Directions | @jaccjournals.bsky.social www.jacc.org/doi/10.1016/...
jacc.org
Fibrinolytic Therapy for Thromboembolic Diseases: Approved Indications and Future Directions
022
mmonrealriete @mmonrealriete.bsky.social · 29/09/2025
010
mmonrealriete @mmonrealriete.bsky.social · 28/09/2025
010
mmonrealriete @mmonrealriete.bsky.social · 25/09/2025
Find it here: www.nature.com/articles/s41...
nature.com
011
mmonrealriete @mmonrealriete.bsky.social · 25/09/2025
Identifying PE patients at increased risk for CTEPH A new #RIETEregistry study Thanks, Stephan and team
010
mmonrealriete @mmonrealriete.bsky.social · 18/09/2025
The VTE-PREDICT SCORE, externally validated using data from the #RIETEregistry Congratulations, Tim and team!
020
mmonrealriete @mmonrealriete.bsky.social · 25/08/2025
010
mmonrealriete @mmonrealriete.bsky.social · 23/08/2025
010
mmonrealriete @mmonrealriete.bsky.social · 23/08/2025
000
mmonrealriete @mmonrealriete.bsky.social · 23/08/2025
Impact of cancer site on outcomes in patients with acute VTE The #RIETEregistry experience
021
mmonrealriete @mmonrealriete.bsky.social · 23/07/2025
In patients with cancer-associated VTE, 90-day outcomes largely vary according to cancer sites Another #RIETEregistry study appearing soon in JACC Advances
000
Reposted by mmonrealriete
VTE Specialist Network @vsnuk1.bsky.social · 18/07/2025
Your 5 minute read for today 🤗 @mmonrealriete.bsky.social pubmed.ncbi.nlm.nih.gov/28120516/
pubmed.ncbi.nlm.nih.gov
Once versus twice daily enoxaparin for the initial treatment of acute venous thromboembolism - PubMed
Background In patients with acute venous thromboembolism (VTE), it is uncertain whether enoxaparin should be administered twice or once daily. Methods We used the RIETE Registry data to compare the 15...
011
mmonrealriete @mmonrealriete.bsky.social · 04/07/2025
Prognostic value of baseline PaCO2 levels on outcome in acute pulmonary embolism A new #RIETEregistry study appearing soon in Arch Bronconeumol
000
mmonrealriete @mmonrealriete.bsky.social · 01/07/2025
000
mmonrealriete @mmonrealriete.bsky.social · 01/07/2025
000
Reposted by mmonrealriete
Saskia Middeldorp @middeldorps.bsky.social · 22/06/2025
Interesting data on influence of race from the RIETE registry. After correction for treatment etc, these differences did not show in multi-variate analysis. #ISTH2025
074
mmonrealriete @mmonrealriete.bsky.social · 28/06/2025
010
mmonrealriete @mmonrealriete.bsky.social · 28/06/2025
000
mmonrealriete @mmonrealriete.bsky.social · 28/06/2025
011
mmonrealriete @mmonrealriete.bsky.social · 28/06/2025
011
mmonrealriete @mmonrealriete.bsky.social · 28/06/2025
011
mmonrealriete @mmonrealriete.bsky.social · 28/06/2025
011
mmonrealriete @mmonrealriete.bsky.social · 28/06/2025
000
mmonrealriete @mmonrealriete.bsky.social · 28/06/2025
000
mmonrealriete @mmonrealriete.bsky.social · 28/06/2025
000
mmonrealriete @mmonrealriete.bsky.social · 28/06/2025
000
Reposted by mmonrealriete
Behnood Bikdeli, MD, MS @bbikdeli.bsky.social · 24/05/2025
Must do better for #PE risk stratification. In an @escardio.bsky.social #EHJ paper we show that a multimarker calculator🌡️outperforms the ESC model. Great leadership by #DavidJimenez @mmonrealriete.bsky.social #RIETE! 👇: tinyurl.com/trpmzbrd
022
mmonrealriete @mmonrealriete.bsky.social · 09/05/2025
010
mmonrealriete @mmonrealriete.bsky.social · 09/05/2025
VTE patients with low LDL-cholesterol levels are at increased risk for major bleeding during anticoagulation, particularly hematoma Another study from the #RIETEregistry Congratulations, Carmine and team!
000
mmonrealriete @mmonrealriete.bsky.social · 29/04/2025
Our manuscript on the impact of hemoglobin values at baseline and clinical outcomes in patients with acute venous thromboembolism has been accepted for publication in the Am J Hematol Congratulations, RIETE team!
021
mmonrealriete @mmonrealriete.bsky.social · 18/04/2025
011
mmonrealriete @mmonrealriete.bsky.social · 18/04/2025
Obese patients with acute PE have a lower mortality rate Find it here: www.rpthjournal.org/action/showP...
rpthjournal.org
011
mmonrealriete @mmonrealriete.bsky.social · 16/04/2025
000
Reposted by mmonrealriete
Unidad de ETV HGUGM @etvgregorio.bsky.social · 04/04/2025
@luciaordieres.bsky.social @mmonrealriete.bsky.social #VTE #thrombosis #VTESky #IMSky #HemeSky
011
Reposted by mmonrealriete
Marc Carrier, MD @marccarriermd.bsky.social · 29/03/2025
Prof. @isabellemahe.bsky.social presents API-CAT at @accintouch.bsky.social published in @nejm.org: Extended anticoagulation with reduced-dose apixaban is noninferior to full-dose for preventing recurrent VTE, with less clinically relevant bleeding 🩸in cancer patients www.nejm.org/doi/full/10....
0109
Reposted by mmonrealriete
jeanconnorsmd.bsky.social @jeanconnorsmd.bsky.social · 29/03/2025
@acc25.bsky.social Isabelle Mahe presents API-CAT Low dose Apixaban noninferior to high dose for recurrent VTE and superior for lower bleeding-another win!
093
Reposted by mmonrealriete
NEJM.org @nejm.org · 29/03/2025
NEJM Editorial Fellow Harleen Marwah, MD, summarizes the API-CAT trial. Read the full trial results: nej.md/41YkRZK #ACC25 #MedSky #CardioSky @accintouch.bsky.social
156